High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors

Assay and Drug Development Technologies

Volumn 12, Issue 1, 2014, Pages 80-86

  Tang, Huaping ^a   Yang, Jing ^a   Shen, Ding Ren ^a   Calambur, Deepa ^a   Witmer, Mark ^a   Wu, Sophie ^a   Carpenter, Brian ^a   Zhang, Yaqun ^a   Gao, Mian ^a   Constantine, Keith ^a   Zhang, Litao ^a   Cvijic, Mary Ellen ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXL KINASE INHIBITOR; GROWTH ARREST SPECIFIC PROTEIN 6; PROTEIN KINASE AXL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BIOLOGICAL ASSAY; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84896697073     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.540     Document Type: Article

References (16)

1. Lemmon MA, Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-1134.
2. Linger RM, Keating AK, Earp HS, Graham DK: TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008;100:35-83.
3. Lemke G, Rothlin CV: Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327-336.
4. Fernandez-Fernandez L, Bellido-Martin L, Garcia de Frutos P: Growth arrest-specific gene 6 (GAS6). An outline of its role in haemostasis and inflammation. Thromb Haemost 2008;100:604-610.
5. Liu E, Hjelle B, Bishop JM: Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci USA 1988;85:1952-1956.
6. Janssen JW, Schulz AS, Steenvoorden AC, et al.: A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 1991;6:2113-2120.
7. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S: Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011;10:1763-1773.
8. Sasaki T, Knyazev PG, Clout NJ, et al.: Structural basis for Gas6-Axl signalling. Embo J 2006;25:80-87.
9. Stitt TN, Conn G, Gore M, et al.: The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995;80:661-670.
10. Linger RM, Keating AK, Earp HS, Graham DK: Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 2010;14:1073-1090.
11. Maree AO, Jneid H, Palacios IF, Rosenfield K, MacRae CA, Fitzgerald DJ: Growth arrest specific gene (GAS) 6 modulates platelet thrombus formation and vascular wall homeostasis and represents an attractive drug target. Curr Pharm Des 2007;13:2656-2661.
12. Rushton L, Winter JJG: 2-Pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors. U.S. Patent WO 2009/007390 A2. January 15, 2009.
13. Goff D, Zhang J, Singh R, et al.: N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors. U.S. Patent WO 2008/083354 A1. July 10, 2008.
14. Pave GA, Firth JD, Stewart L, Rigoreau LJM, Wynne EL: [1, 2, 4]Triazolo[1, 5-a]pyridine and [1, 2, 4]triazolo[1, 5-c]pyrimidine compounds and their use. U.S. Patent WO 2009/047514 A1. April 16, 2009.
15. Li Y, Ye X, Tan C, et al.: Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009;28: 3442-3455.
16. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.